Myungmoon Pharm

017180 · KOSPI · ₩017180 · 명문제약

₩1,136▼ ₩14 (1.22%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩1,097

vs the current price (₩1,136)

Enterprise value
₩52B
Equity value
₩37B
WACC
6.5%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
—
Base
₩1,097
−3.4%
Bull
₩4,975
+337.9%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (1.5%).

Revenue growth

  • 8.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.

  • 7.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.

  • 5.8%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.

  • 4.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.

Business

  • 1.5%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 2%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 0.2%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 11%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.02, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩200B
Net debt (borrowings and leases − cash and deposits)
₩13B
+ Stakes and investments
₩2.8B
Associates, long-term financial assets and deposits (book value)
− Minority interests
₩5.1B
Shares
33,953,454
Share price
₩1,136
Market cap
₩39B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩170B₩186B₩195B₩217B₩233B₩247B₩257B₩265B
Growth11.5%10.0%4.7%8.7%7.3%5.8%4.4%3.0%
EBIT₩964M₩1.9B₩6.8B₩3.3B₩3.5B₩3.7B₩3.9B₩4B
EBIT margin0.6%1.0%3.5%1.5%1.5%1.5%1.5%1.5%
After-tax EBIT₩699M₩1.4B₩5B₩2.4B₩2.5B₩2.7B₩2.8B₩2.9B
+ Depreciation——₩3.8B₩4.3B₩4.7B₩4.9B₩5.1B₩5.3B
− Capital spending₩7.6M₩631M—₩434M₩466M₩493M₩515M₩530M
− Working capital₩5.2B₩4.8B−₩41B₩1.9B₩1.7B₩1.5B₩1.2B₩850M
Free cash flow———₩4.4B₩5B₩5.6B₩6.2B₩6.8B
Discount factor———0.9390.8820.8280.7780.731
Present value———₩4.1B₩4.4B₩4.7B₩4.9B₩5B

Terminal value ₩40B, worth ₩29B today: 56% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩2,874 a share)Now 0.40×₩1,5600.54×₩2,4440.85×₩4,2801.49×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
5.5%₩1,299₩1,353₩1,421₩1,511₩1,637
6.0%₩1,161₩1,196₩1,240₩1,294₩1,367
6.5%₩1,047₩1,070₩1,097₩1,130₩1,172
7.0%₩952₩966₩982₩1,001₩1,024
7.5%₩870₩878₩887₩897₩908

Now (TTM)

Market cap
₩39B
Enterprise value
₩51B
P/E
—
P/B
0.4×
P/S
0.2×
EV/EBITDA
9.4×
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩1,850₩1,819₩2,285₩2,870₩4,730
Market cap₩63B₩62B₩78B₩97B₩161B
P/E33.1×——12.2×—
P/B0.6×0.6×0.9×1.1×2.0×
P/S0.3×0.3×0.5×0.6×1.2×
EV/EBITDA9.7×——15.9×—
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Myungmoon Pharm—0.4×0.2×9.4×0.0%
Samsung Biologics34.7×8.2×15.1×—0.0%
Celltrion28.2×2.5×9.1×—0.0%
Alteogen76.3×27.5×58.0×—0.1%
SK biopharmaceuticals15.2×6.0×7.1×—0.0%
Yuhan23.3×2.3×2.4×30.4×0.8%
HLB—15.5×54.7×—0.0%
Similar companies (median)28.2×7.1×12.1×30.4×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Myungmoon Pharm / 명문제약 / 017180 / KRX:017180

Source: KRX statistical information